STAAR Surgical (STAA) Aktievy
STAAR Surgical Company, tillsammans med sina dotterbolag, designar, utvecklar, tillverkar och säljer fakiska implanterbara linser för ögat och tillbehör för att föra in linserna i ögat. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för STAA från våra riskkontroller.
STAA Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
STAAR Surgical Company Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$25.48 |
| 52 veckors högsta | US$30.81 |
| 52 veckors lägsta | US$15.59 |
| Beta | 1.04 |
| 1 månads förändring | 38.93% |
| 3 månaders förändring | 34.53% |
| 1 års förändring | 39.54% |
| 3 års förändring | -63.65% |
| 5 års förändring | -79.58% |
| Förändring sedan börsintroduktionen | 7.28% |
Senaste nyheter och uppdateringar
STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment
STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid
Apr 09
STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating
Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.
STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares
Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential
Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.Recent updates
STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment
STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid
Apr 09STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating
Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares
Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential
Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.STAA: Post Deal Rejection Concerns Will Keep Shares Under Pressure
Analysts have reduced their average price targets on STAAR Surgical by high single digit dollar amounts to around $13.00. This reflects more cautious views on profit margins and valuation multiples after the failed Alcon deal and a series of Neutral and Underweight ratings.STAA: Post Deal Collapse Uncertainty Will Pressure Shares Until Leadership Path Clears
Narrative Update on STAAR Surgical The analyst price target for STAAR Surgical has been reduced by US$8.75 following a neutral initiation, an Underweight resumption, and cautious commentary from several firms who highlight limited investor appetite until there is greater clarity on the company after the failed Alcon transaction. Analyst Commentary Recent Street research around STAAR Surgical has leaned cautious, with several firms highlighting valuation, execution, and growth risks following the failed Alcon transaction and the subsequent shareholder vote.STAA: Post Alcon Deal Collapse And CEO Exit Will Cap Near Term Upside
Analysts have trimmed their fair value estimate for STAAR Surgical from US$17.41 to US$13.00, reflecting lower assumed revenue growth and a reduced future P/E multiple, alongside cautious commentary around limited buyer interest and uncertainty following the failed Alcon deal. Analyst Commentary Recent Street research has tilted clearly cautious, with several bearish analysts highlighting valuation pressure, deal uncertainty, and limited near term visibility on the business.STAA: Failed Alcon Deal And Takeover Optionality Will Reshape Future Appeal
Analysts have lifted their fair value estimate for STAAR Surgical shares from US$28.00 to US$30.75, reflecting updated assumptions on growth, margins and future P/E multiples after recent debate over the failed Alcon deal and the limited near term appeal highlighted in recent research. Analyst Commentary Recent research has centered on the failed Alcon transaction, shareholder pushback on deal terms, and the limited near term appeal cited by several firms.STAA: Amended Alcon Deal And Activist Push Will Drive Bullish Upside
Analysts have nudged their fair value estimate for STAAR Surgical higher from approximately $25.88 to $26.56. This reflects modestly stronger growth and margin expectations while acknowledging that any amended Alcon deal is unlikely to include a materially higher bid.STAA: Merger Uncertainty Will Restrain Upside Despite Higher All-Cash Offer
Analysts have modestly raised their price target on STAAR Surgical from $16.00 to approximately $17.41 per share, citing slightly improved assumptions for long term revenue growth, profitability, and future valuation multiples, while they continue to monitor ongoing merger term discussions with Alcon. Analyst Commentary Bearish analysts highlight that the postponed shareholder meeting reinforces uncertainty around the timing and ultimate outcome of the proposed acquisition, which in turn clouds visibility on STAAR Surgical's standalone valuation.STAA: Amended Merger Terms And Shareholder Opposition Will Guide Share Price Direction
Analysts have maintained their price target for STAAR Surgical at $25.88, citing limited expected upside due to ongoing merger negotiations and continued uncertainty regarding the acquisition terms. Analyst Commentary Market commentary surrounding STAAR Surgical’s ongoing merger negotiations reflects mixed analyst sentiment, with both cautious and optimistic perspectives regarding the company’s prospects and valuation.STAA: Merger Discussions and Shareholder Opposition Will Shape Path Forward
Analysts have revised STAAR Surgical's price target downward to $16 from previous levels. They cite ongoing shareholder opposition to the proposed merger terms and uncertainty about a potential acquisition price.Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
Analysts have raised their average price target for STAAR Surgical from $20 to $28 per share. They cite the strategic rationale and valuation of the proposed acquisition by Alcon as key drivers for the upward revision.Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price target for STAAR Surgical from $24.63 to $25.88. This reflects the impact of an increased acquisition offer and the perceived strategic value from Alcon's proposed purchase.Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14. Analyst Commentary Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.Introduction Of EVO+ Will Open Market Opportunities In 2025
Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult
Jul 04
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Apr 05Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Feb 14STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Feb 12STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Jan 31STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors
Nov 29Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
Oct 24
EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion
STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
Sep 05Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 10STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear
Aug 05The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing
Jul 12Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
May 27Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher
Apr 26STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge
Apr 05STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue
Mar 25Aktieägarnas avkastning
| STAA | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | 2.7% | -5.3% | -0.2% |
| 1Y | 39.5% | -18.1% | 27.6% |
Avkastning vs industri: STAA översteg US Medical Equipment branschen som gav -18.1 % under det senaste året.
Avkastning vs Marknaden: STAA översteg US marknaden som gav 27.6 % under det senaste året.
Prisvolatilitet
| STAA volatility | |
|---|---|
| STAA Average Weekly Movement | 9.5% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stabil aktiekurs: STAA har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: STAA s veckovolatilitet ( 10% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1982 | 921 | Warren Foust | www.staar.com |
STAAR Surgical Company, tillsammans med sina dotterbolag, designar, utvecklar, tillverkar och säljer fakiska implanterbara linser för ögat och tillbehör för att föra in linserna i ögat. Företaget erbjuder en produktfamilj av implanterbara kollamerlinser (ICL) bestående av EVO ICL, EVO+ ICL, EVO Visian ICL och EVO Viva ICL för användning vid brytningsoperationer för behandling av synfel som närsynthet, översynthet, astigmatism och ålderssynthet. Företaget vänder sig till vårdgivare, inklusive ögonkirurger, syn- och operationscentra, sjukhus, statliga inrättningar och distributörer samt ögonläkare.
STAAR Surgical Company Sammanfattning av grunderna
| STAA grundläggande statistik | |
|---|---|
| Börsvärde | US$1.32b |
| Vinst(TTM) | -US$80.45m |
| Intäkter(TTM) | US$239.44m |
5.3x
P/S-förhållande-15.7x
P/E-förhållandeÄr STAA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| STAA resultaträkning (TTM) | |
|---|---|
| Intäkter | US$239.44m |
| Kostnad för intäkter | US$57.02m |
| Bruttovinst | US$182.42m |
| Övriga kostnader | US$262.87m |
| Intäkter | -US$80.45m |
Senast redovisade vinst
Jan 02, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -1.62 |
| Bruttomarginal | 76.19% |
| Nettovinstmarginal | -33.60% |
| Skuld/egenkapitalförhållande | 0% |
Hur har STAA utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/29 11:13 |
| Aktiekurs vid dagens slut | 2026/04/29 00:00 |
| Intäkter | 2026/01/02 |
| Årlig intjäning | 2026/01/02 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
STAAR Surgical Company bevakas av 21 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Michael Gorman | BTIG |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |